Trevena (TRVN) Q2 2024 earnings summary

Executive summary

• Trevena focuses on CNS disorder medicines, with OLINVYK as its lead product, FDA approved in 2020 and launched in 2021.

• In April 2024, commercial support for OLINVYK was reduced to preserve capital while exploring strategic alternatives, including sale, license, or discontinuation of US sales.

• The company is developing TRV045 (neuropathic pain, epilepsy), TRV734 (opioid use disorder), and TRV250 (migraine).

• Advanced TRV045 with preclinical data supporting its potential for neuropathic pain and epilepsy.

• Completed $12 million financing, including a $2 million non-dilutive tranche and $10 million reduction in ex-US royalty financing liabilities.

Financial highlights

• Net loss for Q2 2024 was $4.9 million ($0.23 per share), compared to $8.0 million ($0.69 per share) in Q2 2023.

• Total revenue for Q2 2024 was $0.3 million, down from $3.0 million in Q2 2023, primarily due to lower license revenue.

• Product revenue for Q2 2024 was $14,000, with royalty revenue from China at $311,000.

• Operating expenses decreased to $6.8 million in Q2 2024 from $9.2 million in Q2 2023.

• Cash and cash equivalents were $16.4 million as of June 30, 2024, down from $33.5 million at year-end 2023.

Outlook and guidance

• Management expects existing cash and cash equivalents will not be sufficient to fund operations for one year after the filing date, raising substantial doubt about the company's ability to continue as a going concern.

• Plans to mitigate risk include raising additional capital, deferring expenses, or pursuing strategic transactions, but success is uncertain.

• Eligible to receive up to $8 million in future tranches based on OLINVYK US partnering and commercial milestones.

• Operating expenses are expected to decrease in 2024 as commercial support for OLINVYK is reduced.

• Strategic review of OLINVYK may result in sale, license, divestiture, or discontinuation of US commercial sales; no assurance of outcome or timing.